BMS, Biocon Team Up To Rekindle Oral Insulin Hopes
This article was originally published in PharmAsia News
Executive Summary
After faltering last year with clinical development of its oral insulin, Biocon’s long hunt for a partner ends with Bristol-Myers Squibb, which signed a carefully worded “exclusive option agreement.”